ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

N-Acetylcysteinamide

Also written as “NPI-001”, “N-Acetylcysteine Amide” and “NACA”.

Its studies are mostly in Usher Syndromes · Cystinosis · Cognitive Dysfunction · Cerebral Amyloid Angiopathy, Familial, led by 2 companies.

Drug pageN-Acetylcysteinamide: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 16, 20256 company-led studies, 4 open or runningNext primary completion: Dec 29, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nacuity Pharmaceuticals42 open or runningphase 3since Dec 16, 2025Apr 17, 2020Apr 2029phase 3 · NCT07710196
Arctic Therapeuticsits history only22 open or runningphase 2since Mar 18, 2026Mar 18, 2026Dec 29, 2026phase 2 · NCT07716865

Also a collaborator on its studies: Blueskin AS.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Nacuity Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2020First study: phase 2 study in Usher SyndromesFirst studyNCT04355689 · 49 enrolled · Australia
  2. Aug 8, 2023Phase 2 study in CystinosisNCT05994534 · 8 enrolled · Australia
  3. Dec 16, 2025Phase 3 study in Retinitis PigmentosaPhase 3 reachedNCT07290530 · 80 planned
  4. Jul 13, 2026Phase 3 study in Retinitis PigmentosaNCT07710196 · 80 planned · United States

Ahead

  1. Apr 2029Primary completion: phase 3 study in Retinitis PigmentosaNCT07710196
  2. Jul 2029Primary completion: phase 3 study in Retinitis PigmentosaNCT07290530

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 Nacuity Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07710196Retinitis Pigmentosa · United States3RecruitingApr 202980
NCT07290530Retinitis Pigmentosa3Not yet recruitingJul 202980
NCT05994534Cystinosis · Australia2CompletedMay 26, 20268
NCT04355689Usher Syndromes · Australia2CompletedJun 20, 202549

How it is read

Names in the registry

  • “NPI-001”, 3 entries
  • “N-Acetylcysteine Amide”, 1 entry
  • “NACA”, 1 entry
  • “N-acetylcysteine amide”, 1 entry

Codes read as this program: NPI001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.